{"id":"W3030666284","doi":"10.1200/jco.19.03158","title":"Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Carboplatin; Lung cancer; Internal medicine; Adverse effect; Oncology; Paclitaxel; Chemotherapy; Population; Clinical endpoint; Cancer; Surgery; Clinical trial; Nivolumab; Cisplatin; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009795664,0.0003767933,0.003217876,0.0001690017,0.00004842643,0.00001344723,0.0002449736,0.0005108485,0.0003777537],"category_scores_gemma":[0.0004281618,0.000234774,0.0004753133,0.0004241755,0.0003870213,0.0001349224,0.0000508763,0.001012277,0.00000105937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007053342,"about_ca_system_score_gemma":0.004559584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003631231,"about_ca_topic_score_gemma":0.0005393766,"domain_scores_codex":[0.9948348,0.0002295647,0.00354039,0.0004274524,0.0005633811,0.0004043536],"domain_scores_gemma":[0.994675,0.0009851546,0.003168487,0.000302652,0.0004198594,0.0004488402],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.644846,0.0009405105,0.1630821,0.0002051406,0.002656844,0.00064664,0.003149575,0.00007187459,0.0007946821,0.000002355358,0.0005838381,0.1830204],"study_design_scores_gemma":[0.4533468,0.06318582,0.4417058,0.0006655134,0.001397213,0.0004977534,0.00202542,0.002847498,0.001887286,0.000007294976,0.03181199,0.0006215275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795666,0.001801332,0.0001833633,0.01618979,0.0006938393,0.0008852474,0.00001076049,0.00001717487,0.0006518884],"genre_scores_gemma":[0.981686,0.008407788,0.002292366,0.007023559,0.0003198951,0.0000140252,0.000003332145,0.00006350648,0.0001895543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2786238,"threshold_uncertainty_score":0.9573804,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06888573817441451,"score_gpt":0.4097461346332562,"score_spread":0.3408603964588417,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}